Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × Decitabine × Clear all
NCT00114257 2013-02-11

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
LymphoidMyeloidOther hematologic neoplasm

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00043134 2010-04-13

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 3 Unknown
220 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative